In:
Current Neuropharmacology, Bentham Science Publishers Ltd., Vol. 21, No. 5 ( 2023-05), p. 1241-1272
Abstract:
Parkinson’s disease (PD) is a debilitating neurodegenerative multisystem disorder leading
to motor and non-motor symptoms in millions of individuals. Despite intense research, there is still no cure, and early disease biomarkers are lacking. Animal models of PD have been inspired by
basic elements of its pathogenesis, such as dopamine dysfunction, alpha-synuclein accumulation, neuroinflammation and disruption of protein degradation, and these have been crucial for a deeper
understanding of the mechanisms of pathology, the identification of biomarkers, and evaluation of novel therapies. Imaging biomarkers are non-invasive tools to assess disease progression and response
to therapies; their discovery and validation have been an active field of translational research. Here, we highlight different considerations of animal models of PD that can be applied to
future research, in terms of their suitability to answer different research questions. We provide the reader with important considerations of the best choice of model to use based on the disease features
of each model, including issues related to different species. In addition, positron emission tomography studies conducted in PD animal models in the last 5 years are presented. With a variety
of different species, interventions and genetic information, the choice of the most appropriate model to answer research questions can be daunting, especially since no single model recapitulates all aspects
of this complex disorder. Appropriate animal models in conjunction with in vivo molecular imaging tools, if selected properly, can be a powerful combination for the assessment of novel therapies
and developing tools for early diagnosis.
Type of Medium:
Online Resource
ISSN:
1570-159X
DOI:
10.2174/1570159X21666230216101659
Language:
English
Publisher:
Bentham Science Publishers Ltd.
Publication Date:
2023
detail.hit.zdb_id:
2119376-9
Permalink